呼吸器・免疫内科学

• ホーム
• 研究業績
• 総説

総説

2023年

• The role of semaphorins in allergic diseases.
  Naito M, Kumanogoh A.
  Allergol Int. 2023 Aug 25:S1323-8930(23)00082-5.
• Pathophysiological functions of semaphorins in the sympathetic nervous system.
  Mizuno Y, Nakanishi Y, Kumanogoh A.
  Inflamm Regen. 2023 Jun 8;43(1):30.
• The Ragulator complex: delving its multifunctional impact on metabolism and beyond.
  Tsujimoto K, Takamatsu H, Kumanogoh A.
  Inflamm Regen. 2023 May 12;43(1):28.
• Group 2 innate lymphoid cells and their surrounding environment.
  Naito M, Kumanogoh A.
  Inflamm Regen. 2023 Mar 20;43(1):21.
• Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases.
  Kato Y, Morita T, Kumanogoh A.
  Inflamm Regen. 2023 Jan 6;43(1):1.

2022年

• Current status and prospects of IL-6-targeting therapy.
  Narazaki M, Kishimoto T.
  Expert Rev Clin Pharmacol. 2022 May;15(5):575-592.
• Crosstalk between axon guidance signaling and bone remodeling.
  Nakanishi Y, Kang S, Kumanogoh A.
  Bone. 2022 Apr;157:116305.
• Axon guidance molecules in immunometabolic diseases.
  Nakanishi Y, Kang S, Kumanogoh A.
  Inflamm Regen. 2022 Jan 19;42(1):5.

2021年

• Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma.
  Abe Y, Suga Y, Fukushima K, Ohata H, Niitsu T, Nabeshima H, Nagahama Y, Kida H, Kumanogoh A.
  Int J Mol Sci. 2021 Dec 22;23(1):83.
• Imaging Assessment of Tumor Response in the Era of Immunotherapy.
  Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H.
  Diagnostics (Basel). 2021 Jun 5;11(6):1041.
• Neural guidance factors as hubs of immunometabolic cross-talk.
  Nakanishi Y, Kang S, Kumanogoh A.
  Int Immunol. 2021 Nov 25;33(12):749-754.
• Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
  Shima Y.
  Cells. 2021 May 4;10(5):1104.

2020年

• The future of microfluidics in immune checkpoint blockade.
  Briones J, Espulgar W, Koyama S, Takamatsu H, Tamiya E, Saito M.
  Cancer Gene Ther. 2020 Oct 27. doi: 10.1038/s41417-020-00248-7.
• Revisiting Cell Death Responses in Fibrotic Lung Disease: Crosstalk between Structured and Non-Structured Cells.
  Fukushima K, Satoh T, Kida H, Kumanogoh A.
  Diagnostics (Basel). 2020 Jul 21;10(7):504.
• Host Immune Response and Novel Diagnostic Approach to NTM Infections.
  Abe Y, Fukushima K, Hosono Y, Matsumoto Y, Motooka D, Ose N, Nakamura S, Kitada S, Kida H, Kumanogoh A.
  Int J Mol Sci. 2020 Jun 18;21(12):4351.
• Historical overview of the interleukin-6 family cytokine.
  Kang S, Narazaki M, Metwally H, Kishimoto T.
  J Exp Med. 2020 May 4;217(5). pii: e20190347.
• The spectrum of macrophage activation by immunometabolism.
  Kang S, Kumanogoh A.
  Int Immunol. 2020 Jun 26;32(7):467-473.

2019年

• Targeting Interleukin-6 Signaling in Clinic.
  Kang S, Tanaka T, Narazaki M, Kishimoto T.
  Immunity. 2019 Apr 16;50(4):1007-1023.
• The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.
  Shima Y.
  Mod Rheumatol. 2019 Mar;29(2):294-301. Epub 2019 Feb 6.

2018年

• The Two-Faced Cytokine IL-6 in Host Defense and Diseases.
  Narazaki M, Kishimoto T.
  Int J Mol Sci. 2018 Nov 9;19(11).
• Roles of Lamtor1 in Macrophages, CD4+ T-cells, and Regulatory T-cells.
  Kimura T, Kumanogoh A, Okada M.
  Crit Rev Immunol. 2018;38(5):403-414.
• Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment.
  Koyama S, Nagatomo I, Kijima T, Kumanogoh A.
  Oncotarget. 2018 Aug 24;9(66):32552-32553.
• The role of semaphorins in immune responses and autoimmune rheumatic diseases.
  Nishide M, Kumanogoh A.
  Nat Rev Rheumatol. 2018 Jan;14(1):19-31. Epub 2017 Dec 7.

2017年

• Wilms' tumor gene 1 (WT1) peptide vaccine therapy for hematological malignancies: from CTL epitope identification to recent progress in clinical studies including a cure-oriented strategy.
  Oka Y, Tsuboi A, Nakata J, Nishida S, Hosen N, Kumanogoh A, Oji Y, Sugiyama H.
  Oncol Res Treat. 2017 Oct 18. 40(11) Epub ahead of print
• Interleukin (IL-6) Immunotherapy.
  Tanaka T, Narazaki M, Kishimoto T.
  Cold Spring Harb Perspect Biol. 2017 Aug 4. Epub ahead of print
• The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
  Narazaki M, Tanaka T, Kishimoto T.
  Expert Rev Clin Immunol. 2017 Jun;13(6):535-551. Epub 2017 Mar 3.
• Role of Gut Microbiota in Rheumatoid Arthritis.
  Maeda Y, Takeda K.
  J Clin Med. 2017 Jun 9;6(6). pii: E60.

2016年

• Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.
  Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Oji Y, Oka Y, Sugiyama H.
  Stem Cell Investig. 2016 Dec 9;3:90.
• The role of Sema4A in angiogenesis, immune responses, carcinogenesis, and retinal systems.
  Ito D, Kumanogoh A.
  Cell Adh Migr. 2016 Nov;10(6):692-699. Epub 2016 Oct 13.
• Altered composition of gut microbiota in rheumatoid arthritis patients.
  Maeda Y, Kumanogoh A, Takeda K.
  Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(1):59-63.
• Immunotherapeutic implications of IL-6 blockade for cytokine storm.
  Tanaka T, Narazaki M, Kishimoto T.
  Immunotherapy. 2016 Jul;8(8):959-70.

2015年

• Preventive Role of Tetraspanin CD9 in Systemic Inflammation of Chronic Obstructive Pulmonary Disease.
  Takeda Y, Suzuki M, Jin Y, Tachibana I.
  Am J Respir Cell Mol Biol. 2015 Dec;53(6):751-60.
• Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.
  Ogata A, Morita T, Yoshida Y, Tanaka T.
  Ther Deliv. 2015 Mar;6(3):283-95.

2014年

• Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.
  Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Nakae Y, Takashima S, Oji Y, Oka Y, Kumanogoh A, Sugiyama H.
  Expert Rev Hematol. 2014 Oct;7(5):671-81. Epub 2014 Sep 4.
• IL-6 in inflammation, immunity, and disease.
  Tanaka T, Narazaki M, Kishimoto T.
  Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295.
• Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors.
  Tanaka T, Hishitani Y, Ogata A.
  Biologics. 2014 Apr 7;8:141-53.
• Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis.
  Takeda Y, Tsujino K, Kijima T, Kumanogoh A.
  Patient Prefer Adherence. 2014 Mar 21;8:361-70.
• A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
  Tanaka T, Narazaki M, Ogata A, Kishimoto T.
  Semin Immunol. 2014 Feb;26(1):88-96. Epub 2014 Mar 1.

2013年

• Immunological functions of the neuropilins and plexins as receptors for semaphorins.
  Kumanogoh A, Kikutani H.
  Nat Rev Immunol. 2013 Nov;13(11):802-14.
• Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?
  Tanaka T.
  Immunotherapy. 2013 Jul;5(7):695-7.
• Semaphorins in bone development, homeostasis, and disease.
  Kang S, Kumanogoh A.
  Semin Cell Dev Biol. 2013 Mar;24(3):163-71. Epub 2012 Sep 27.
• Multiple myeloma-initiating cells.
  Hosen N.
  Int J Hematol. 2013 Mar;97(3):306-12.
• Involvement of STAT3 in immune evasion during lung tumorigenesis.
  Kida H, Ihara S, Kumanogoh A.
  Oncoimmunology. 2013 Jan 1;2(1):e22653.

2012年

• Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.
  Ogata A, Hirano T, Hishitani Y, Tanaka T.
  Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:27-42. Epub 2012 Mar 5.
• Diverse roles for semaphorin-plexin signaling in the immune system.
  Takamatsu H, Kumanogoh A.
  Trends Immunol. 2012 Mar;33(3):127-35. Epub 2012 Feb 9.
• Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.
  Ogata A, Tanaka T.
  Int J Rheumatol. 2012;2012:946048. Epub 2012 Jan 18.

2011年

• Therapeutic targeting of the interleukin-6 receptor.
  Tanaka T, Narazaki M, Kishimoto T.
  Annu Rev Pharmacol Toxicol. 2012;52:199-219. Epub 2011 Sep 9.
• The role of immune semaphorins in multiple sclerosis.
  Okuno T, Nakatsuji Y, Kumanogoh A.
  FEBS Lett. 2011 Dec 1;585(23):3829-35. Epub 2011 Mar 22.
• Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
  Tanaka T, Narazaki M, Kishimoto T.
  FEBS Lett. 2011 Dec 1;585(23):3699-709. Epub 2011 Mar 21.